Blog

(From : http://www.iposgoode.ca - December 4 , 2018 )

This term, I had the pleasure of being placed at Sandoz Canada as part of Osgoode’s Intellectual Property (IP) Law and Technology Intensive Program.

(From : http://www.iposgoode.ca - December 4 , 2018 )

During my IP Intensive internship with Markham’s business acceler

(From : http://feeds2.feedburner.com - December 4 , 2018 )

Sean Flynn, Peter Jaszi, and Mike Carroll write: On Wednesday the South African National Assembly vote on the Copyright Amendment Bill, which includes a new “fair use” right.

(From : http://www.ip-watch.org - December 4 , 2018 )

Sean Flynn, Peter Jaszi, and Mike Carroll write: On Wednesday the South African National Assembly vote on the Copyright Amendment Bill, which includes a new “fair use” right.

(From : http://feeds2.feedburner.com - December 4 , 2018 )

Eve Gray and Desmond Oriakhogba write: The publishing industry is making a mad dash to defeat South Africa’s adoption of a fair use rights in Parliament on Wednesday.

(From : http://www.ip-watch.org - December 4 , 2018 )

Eve Gray and Desmond Oriakhogba write: The publishing industry is making a mad dash to defeat South Africa’s adoption of a fair use rights in Parliament on Wednesday.

(From : http://www.ip-watch.org - December 4 , 2018 )

NEW YORK -- United States intellectual property stakeholders from academic, business and legal backgrounds gathered recently to discuss how to increase public support to strengthen the intellectual property rights system in the US, in light of Chi

(From : http://feeds2.feedburner.com - December 4 , 2018 )

NEW YORK -- United States intellectual property stakeholders from academic, business and legal backgrounds gathered recently to discuss how to increase public support to strengthen the intellectual property rights system in the US, in light of Chi

(From : http://www.ip-watch.org - December 4 , 2018 )

Initiative for Medicines, Access & Knowledge (I-MAK) released a new study yesterday showing that the rheumatoid arthritis drug Enbrel has been overpatented by drugmaker Amgen, which has filed a total of 57 patents on the drug in the United Sta

(From : http://feeds2.feedburner.com - December 4 , 2018 )

Initiative for Medicines, Access & Knowledge (I-MAK) released a new study yesterday showing that the rheumatoid arthritis drug Enbrel has been overpatented by drugmaker Amgen, which has filed a total of 57 patents on the drug in the United Sta